Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 27; p. vi313
Main Authors Weisel, K., Palumbo, A., Chanan-Khan, A., Nooka, A.K., Spicka, I., Masszi, T., Beksac, M., Hungria, V., Munder, M., Mateos, M.-V., Mark, T.M., Spencer, A., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Sonneveld, P.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.10.2016
Online AccessGet full text

Cover

Author Spicka, I.
Mateos, M.-V.
Munder, M.
Beksac, M.
Deraedt, W.
Palumbo, A.
Amin, H.
Qin, X.
Weisel, K.
Nooka, A.K.
Spencer, A.
Hungria, V.
Sonneveld, P.
Masszi, T.
Mark, T.M.
Schecter, J.
Qi, M.
Chanan-Khan, A.
Ahmadi, T.
Author_xml – sequence: 1
  givenname: K.
  surname: Weisel
  fullname: Weisel, K.
  organization: Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tuebingen, Germany
– sequence: 2
  givenname: A.
  surname: Palumbo
  fullname: Palumbo, A.
  organization: Department of Hematology, University of Turin, Turin, Italy
– sequence: 3
  givenname: A.
  surname: Chanan-Khan
  fullname: Chanan-Khan, A.
  organization: Division of Hematology & Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, USA
– sequence: 4
  givenname: A.K.
  surname: Nooka
  fullname: Nooka, A.K.
  organization: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA
– sequence: 5
  givenname: I.
  surname: Spicka
  fullname: Spicka, I.
  organization: Clinical Department of Haematology, 1st Medical Department, Charles University in Prague, Prague, Czech Republic
– sequence: 6
  givenname: T.
  surname: Masszi
  fullname: Masszi, T.
  organization: Department of Haematology and Stem Cell Transplantation, St László Hospital, Semmelweis University, Budapest, Hungary
– sequence: 7
  givenname: M.
  surname: Beksac
  fullname: Beksac, M.
  organization: Department of Hematology, Ankara University, Ankara, Turkey
– sequence: 8
  givenname: V.
  surname: Hungria
  fullname: Hungria, V.
  organization: Irmandade Da Santa Casa De Misericordia De São Paulo, São Paulo, Brazil
– sequence: 9
  givenname: M.
  surname: Munder
  fullname: Munder, M.
  organization: Third Department of Medicine, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
– sequence: 10
  givenname: M.-V.
  surname: Mateos
  fullname: Mateos, M.-V.
  organization: University Hospital of Salamanca/IBSAL, Salamanca, Spain
– sequence: 11
  givenname: T.M.
  surname: Mark
  fullname: Mark, T.M.
  organization: Weill Cornell Medical College, New York, NY, USA
– sequence: 12
  givenname: A.
  surname: Spencer
  fullname: Spencer, A.
  organization: Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
– sequence: 13
  givenname: M.
  surname: Qi
  fullname: Qi, M.
  organization: Janssen Research & Development, LLC, Spring House, PA, USA
– sequence: 14
  givenname: J.
  surname: Schecter
  fullname: Schecter, J.
  organization: Janssen Research & Development, LLC, Raritan, NJ, USA
– sequence: 15
  givenname: H.
  surname: Amin
  fullname: Amin, H.
  organization: Janssen Research & Development, LLC, Raritan, NJ, USA
– sequence: 16
  givenname: X.
  surname: Qin
  fullname: Qin, X.
  organization: Janssen Research & Development, LLC, Horsham, PA, USA
– sequence: 17
  givenname: W.
  surname: Deraedt
  fullname: Deraedt, W.
  organization: Janssen Research & Development, Beerse, Belgium
– sequence: 18
  givenname: T.
  surname: Ahmadi
  fullname: Ahmadi, T.
  organization: Janssen Research & Development, LLC, Spring House, PA, USA
– sequence: 19
  givenname: P.
  surname: Sonneveld
  fullname: Sonneveld, P.
  organization: Department of Hematology, Erasmus MC, Rotterdam, Netherlands
BookMark eNqFkE1PGzEQhq2KSg209x7nmEgs-GO_zA0FSpFAVCntdTVrO8JovV7ZTiD9cfy2OkqvqKcZjZ535p33mByNfjSEfGX0jFEpznHMA3Xu9ItoqjPKPpAZq2pZtLRkR2RGJRdFU4nyEzmO8ZlSWksuZ-TtxxNGAwICjto7G42GmDZ6B34NGgOmjds47E-h9yGZPxnpIaOgzSs6k7I6-4D51W-9gG38D7WH7AgTJmvGFGE-pbiAF5ueIJgBp_11H3K_DqiSDztwmyHZaTDgdmbwDmG-Wt3fLy5gefnz8WH1mXxc4xDNl3_1hPz6dv24_F7cPdzcLi_vCiU4Y0Wr2laUdd0wymnFWmEUY0pSSbHirUFZYt1LUTHeNLQRyJXsqSq5wrVoeKnECaGHvSr4GLO_bgrWYdh1jHb7_LtD_t0h_46yLLk4SEz2tbUmdFHlr5XRNhiVOu3t--K_jRqTLQ
CitedBy_id crossref_primary_10_1080_0284186X_2020_1807600
ContentType Journal Article
Copyright 2016 European Society for Medical Oncology
Copyright_xml – notice: 2016 European Society for Medical Oncology
DBID 6I.
AAFTH
AAYXX
CITATION
DOI 10.1093/annonc/mdw375.01
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1569-8041
EndPage vi313
ExternalDocumentID 10_1093_annonc_mdw375_01
S092375341944533X
GroupedDBID ---
-E4
.2P
.86
.I3
.XZ
.ZR
08P
0R~
1TH
23M
2WC
4.4
482
48X
53G
5GY
5VS
5WA
6.Y
6I.
6J9
70D
AABJS
AABMN
AAEDW
AAESY
AAFTH
AAIAV
AAIYJ
AAJKP
AAJQQ
AAKAS
AAKUH
AAMVS
AAOGV
AAPNW
AAXUO
ABEUO
ABIXL
ABJNI
ABKDP
ABLJU
ABNKS
ABOCM
ABQLI
ABVKL
ABZBJ
ACGFO
ACGFS
ACIMA
ACPRK
ACUFI
ACUTO
ADBBV
ADEIU
ADEYI
ADHKW
ADHZD
ADJQC
ADOCK
ADORX
ADQLU
ADRIX
ADRTK
ADYVW
ADZCM
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AENEX
AENZO
AEPUE
AEWNT
AFIYH
AFOFC
AFXEN
AGINJ
AGKEF
AGSYK
AHMBA
AHXPO
AIAGR
AIJHB
AIKOY
AITUG
ALMA_UNASSIGNED_HOLDINGS
ALUQC
AMRAJ
APIBT
APWMN
ASMCH
AWCFO
AXUDD
AZQFJ
BAWUL
BAYMD
BEYMZ
BGYMP
BHONS
BTRTY
BVRKM
CASEJ
CDBKE
CKLRP
COF
CS3
CZ4
DAKXR
DIK
DILTD
DPORF
DPPUQ
D~K
E3Z
EBS
EE~
EJD
F9B
FDB
GJXCC
GX1
H5~
HAR
HW0
HZ~
I09
IH2
IOX
J21
KAQDR
KOM
KOP
KQ8
KSI
KSN
M-Z
M41
M49
MHKGH
N9A
NCXOZ
NGC
NOYVH
NU-
NVLIB
O9-
OAWHX
ODMLO
OJQWA
OK1
OVD
P2P
P6G
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
ROL
ROX
RW1
RXO
TCURE
TEORI
TJX
TR2
W8F
WOQ
X7H
YAYTL
YFH
YKOAZ
ZKX
~91
0SF
0U7
AALRI
AAUQX
AAYXX
ABQTQ
ABSAR
ABSMQ
ACMRT
ACPQN
ADVLN
AEHUL
AEKPW
AFETI
AFJKZ
AFSHK
AGKRT
AKRWK
AQKUS
ASPBG
ATTQO
AVWKF
AZFZN
BGNMA
BZKNY
C1A
CAG
CITATION
DL5
EX3
FEDTE
H13
HVGLF
IHE
KC5
KDC
LAK
M4Y
MBLQV
NTWIH
NU0
PB-
QBD
RNI
ROZ
RPX
RZC
RZE
RZF
RZO
SDH
TMA
U2A
WOW
ZXP
ID FETCH-LOGICAL-c3211-8c883466710205183ec11c9090a528ea94a6b9351277073a2c9b0c42caf3724c3
IEDL.DBID ABVKL
ISSN 0923-7534
IngestDate Thu Sep 26 17:53:56 EDT 2024
Fri Feb 23 02:47:05 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3211-8c883466710205183ec11c9090a528ea94a6b9351277073a2c9b0c42caf3724c3
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S092375341944533X
ParticipantIDs crossref_primary_10_1093_annonc_mdw375_01
elsevier_sciencedirect_doi_10_1093_annonc_mdw375_01
PublicationCentury 2000
PublicationDate 2016-10-01
2016-10-00
PublicationDateYYYYMMDD 2016-10-01
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-01
  day: 01
PublicationDecade 2010
PublicationTitle Annals of oncology
PublicationYear 2016
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
SSID ssj0006929
Score 2.238361
SourceID crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage vi313
Title Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR
URI https://dx.doi.org/10.1093/annonc/mdw375.01
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ZS8NAEF48QHwRT7yZBx9aMDbJbi7falVErUo9KL6EvYIF25QeXj_O3-ZssxVFRPApIcwmYWd35pudi5CdOJYBAuXAZPRwh3GuHRFE0nGVVBLhdyS1OdCvX4Qnt-y0GTQnSG2cC2PCKq3sL2T6SFrbJxU7m5Vuq1W5dhGbINhmaIYzBC3NSTLtI_rF3TldPbg7O_8UyGHiFyX3fOqYAdZbiba86fWSdyQa_8_4qj3bGeaHdvqicY7nyZyFilAt_maBTOjOIpmpW2f4Enm_ekAVBBRQ3agc-aUVjKrFQp6BMiW9h-1hm4tdECai9g1JBCApKP3CTedojlhbQ-nwTpXhqf8HlSFqdcDWYe1DqTvol8Ec44LJh-mar-c9vM96oxY-rzCOVYT2q37M2xxKjUa9Xt6HWvX65rKxTG6Pj25qJ45tx-BIimaiE8s4piwMDSbBrRxTLT1PJm7i8sCPNU8YD0VCEUFEEQoO7stEuJL5kmc08pmkK2QKZ1uvEvCQQHDmu5lpvx6FQoeZRttGMSmY8tw1Uh6zIe0WVTfSwltO04JlacGy1PXWCB3zKf22clJUCr-OWv_XqA0yi4ApLIL5NsnUoDfUWwhKBmLbLjq8XtSal_cf0sblrw
link.rule.ids 315,783,787,27581,27936,27937,45675
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6VVAIuqLQgChTm0EMiYWJ71y9uaaAKbVxQmla5WfuyiETiKA-g_XH9bZ2NN4iqQkjcLGvGtnbWM9_svAAO01RFBJQjW9EjPC6E8WSUKM_XSiuC34ky9kA_P4t7F_xkFI22oLuphbFplU731zp9ra3dnbZbzfZsPG6f-4RNCGxzcsM5gZbRA9gmNJBEDdjuHF2e9n8r5DgL65Z7IfMsg4tWki9vZ71UU0XO_0961Hs3GeaedfrD4hzvwBMHFbFTf81T2DLTXXiYu2D4Htx8_UYmCBmSudEVyctoXHeLxapEbVt6ryariZDvUNqM2msikUikqM0vYSdHC8LaBpsfL3ULfyz-QWWJxlN0fVgX2JwtFy20x7ho62Fm9u3VnK7L-XqEzxVuchVxcmW-VxOBzcEgz1sfsNs5H34ZPIOL40_Dbs9z4xg8xchN9FKVpozHscUk9CunzKggUJmf-SIKUyMyLmKZMUIQSUKKQ4Qqk77ioRIlS0Ku2HNo0GqbF4ABEUjBQ7-049eTWJq4NOTbaK4k14G_D62NGIpZ3XWjqKPlrKhFVtQiK_xgH9hGTsWdnVOQUfgr18v_4noLj3rDvF_0P5-dvoLHBJ7iOrHvNTSW85U5IICylG_cBrwFh0_m6A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+3+randomised+study+of+daratumumab%2C+bortezomib+and+dexamethasone+%28DVd%29+vs+bortezomib+and+dexamethasone+%28Vd%29+in+patients+%28pts%29+with+relapsed+or+refractory+multiple+myeloma+%28RRMM%29%3A+CASTOR&rft.jtitle=Annals+of+oncology&rft.au=Weisel%2C+K.&rft.au=Palumbo%2C+A.&rft.au=Chanan-Khan%2C+A.&rft.au=Nooka%2C+A.K.&rft.date=2016-10-01&rft.pub=Elsevier+Ltd&rft.issn=0923-7534&rft.eissn=1569-8041&rft.volume=27&rft.spage=vi313&rft.epage=vi313&rft_id=info:doi/10.1093%2Fannonc%2Fmdw375.01&rft.externalDocID=S092375341944533X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon